ABSTRACT

Objective We studied the psychometric properties of the 12-item short version of the Berger HIV stigma scale and assessed the correlates of HIV-related stigma among adults living with HIV on the Kenyan coast.

Design Cross-sectional study.

Setting Comprehensive Care and Research Centre in the Kilifi County Hospital.

Participants Adults living with HIV on combination antiretroviral therapy were recruited and interviewed between February and April 2018 (n=450).

Main outcome measures HIV-related stigma.

Results 450 participants with a median age of 43 years (IQR=36–50) took part in the study. Of these, 356 (79.1%) were female. Scale reliability and validity were high (alpha=0.80, test–retest reliability intraclass correlation coefficient=0.92). Using confirmatory factor analysis, we observed that the 12-item short version of the HIV stigma scale had a good fit for its hypothesised model (Comparative Fit Index=0.966, Tucker Lewis Index=0.955, root mean square error of approximation=0.044).

Multigroup confirmatory factor analysis indicated measurement invariance across gender and age groups as ΔCFI was ≤0.01. Multivariate linear regression established that being female (β=2.001, 95% CI: 0.21 to 3.80, p=0.029), HIV status non-disclosure (β=4.237, 95% CI: 1.27 to 7.20, p=0.005) and co-occurrence of depressive and anxiety symptoms (β=6.670, 95% CI: 3.40 to 9.94, p<0.001) were significant predictors of perceived HIV-related stigma and that these variables accounted for 10.2% of the explained variability in HIV-related stigma among adults living with HIV from Kilifi.

Conclusions Our results indicate that the 12-item short version of the HIV stigma scale is a valid and reliable measure of HIV stigma in Kenya. Furthermore, our study indicates that interventions aimed at reducing stigma need to take into account gender to address the specific needs of women, people who have not disclosed their HIV status, and those exhibiting symptoms of depression and anxiety, thereby improving their quality of life.

INTRODUCTION

HIV/AIDS remains a considerable public health concern globally, with sub-Saharan Africa (SSA) bearing the most HIV-related disease burden.1 Despite SSA making up about 11% of the earth’s population, it is the world’s epicentre of HIV/AIDS. By the close of 2019, an estimated 38 million people were living with HIV globally, with an estimated 68% living in SSA, accounting for two-thirds of all individuals living with HIV.1 Between 2010 and mid-2020, there has been an upsurge in the number of people accessing antiretroviral therapy (ART) (7.8–26 million).1 Further, between 2010 and 2019, new HIV infections declined by an estimated 16% from 2.1 million/year to 1.7 million/year, and AIDS-related deaths dropped from 1.1 million to around 690 000 per year.1 By the end of 2019, an estimated 1.5 million Kenyans were living with HIV, with 42 000 new infections and 21 000 AIDS-related deaths reported.5 Estimates show that between 80% and 90% of the people living with HIV/AIDS (PLWHA) in Kenya are adults.3 Additionally, 75% of adults in Kenya are reported to be on antiretroviral treatment.
Erving Goffman\(^1\) defined stigma as a process through which individuals are ‘disqualified from full social acceptance’ due to an undesirable ‘mark’ or ‘label.’ This label can either be a physical, health or behavioural attribute that is regarded as ‘deeply discrediting.’\(^4\) In this study, the label is HIV seropositive status. Additionally, stigma, defined as a ‘mark,’ sets a person apart from others and links the person to undesirable characteristics such as stereotypes.\(^5\) HIV-related stigma among PLWHA is prevalent throughout SSA.\(^6\) HIV-related stigma has been identified as a severe obstacle in the way of effective responses to HIV.\(^7\)

Although efforts have been scaled up to raise awareness and increase public knowledge about HIV since the epidemic started decades ago, social stigma is still associated with the disease.\(^8\) Research has demonstrated that stigma keeps people from adopting HIV preventive behaviours and accessing needed care and treatment,\(^9\) negatively impacting their health and well-being. Among women living with HIV, the decision to disclose their HIV seropositive status is likely affected by perceived stigma.\(^10\)

From previous research, HIV stigma experienced by PLWHA can either be enacted, anticipated or internalised.\(^11\) Enacted stigma includes an individual’s experiences, prejudice, and/or discrimination from others because of one’s HIV status. Anticipated stigma includes an individual’s expectation of experiencing enacted stigma, while internalised stigma refers to the extent to which PLWHA have adopted negative feelings and beliefs about PLWHA.\(^12\)

A variety of instruments designed to measure HIV-related stigma have been published.\(^13\)–\(^21\) Berger’s 40-item HIV stigma scale (HSS-40) is the most commonly used instrument and one of the few instruments covering all stigma mechanisms affecting PLWHA.\(^12\) It takes up to 25 min to complete the HSS-40,\(^22\) which may limit its application, especially in extensive surveys. Though shortened versions covering 25\(^22\) and 32\(^23\) items of the HSS exist, the 12-item HSS (HSS-12)\(^14\) version of the Berger HSS was examined in the present study as it facilitates the inclusion of HIV stigma in more extensive surveys. Furthermore, it has comparable psychometric properties to the full-length scale.\(^14\) While evidence from other parts of the world\(^34\) indicates that the HSS-12 is psychometrically sound, we are unaware of any study that has reported these scales’ psychometric properties in the SSA context.

Empirical evidence indicates that sociodemographic characteristics such as age,\(^24\)–\(^25\) gender,\(^25\)–\(^26\) employment,\(^26\) educational attainment,\(^29\)–\(^31\) and marital status,\(^32\) are significantly correlated with HIV-related stigma. However, the directionality is inconsistent. An explanation for the different findings regarding correlates and predictors of HIV-related stigma might be due to the diverse research strategies applied and the sample composition. Research shows that stigma and disclosure of HIV status are interrelated phenomena for PLWHA.\(^33\) Furthermore, persons who have not disclosed their HIV status exhibit higher levels of perceived HIV-related stigma and greater levels of concern about HIV disclosure.\(^34\)

Despite the abundance of published reports on HIV-related stigma and its predictors among specific subgroups of the adult population, there is a paucity of research findings focusing on predictors of HIV-related stigma across the entire adult population. Further, no study in the SSA context has tested for the validity and reliability of the HSS-12. This study aims to determine the correlates of HIV-related stigma among adults living with HIV from Kilifi, Coastal Kenya. Specifically, the study aims to: (1) examine the psychometric properties of the 12-item Berger Stigma Scale and (2) establish the correlates of stigma among adults living with HIV in Kilifi.

METHODS

Study setting

This cross-sectional study was conducted at the Kenya Medical Research Institute-Wellcome Trust Research Programme (KEMRI), Centre for Geographic Medicine Research (Coast), Kilifi, Kenya. It was based at the Comprehensive Care and Research Centre (CCRC) in the Kilifi County Hospital (KCH). The majority of Kilifi County residents are poor (71.4% live below the poverty line), lack formal education, and earn a living mainly through subsistence farming or fishing.\(^35\)–\(^37\) HIV prevalence in adults is estimated to be at 4.5%.\(^38\) The CCRC offers clinical services such as management of opportunistic infections, HIV testing and counselling, family planning, nutritional counselling, cervical cancer screening, the dispensation of ART and serves as a research facility. About 60 patients are seen daily. By 2020, the clinic has enrolled over 9000 patients of all ages.

Study participants

This data are part of a larger project focusing on diverse outcomes in adults living with HIV, including mental health and health-related quality of life. A cross-sectional survey of 450 study participants among patients attending an HIV care and treatment clinic at the KCH was conducted between February and April 2018 (figure 1). The participation criteria were age (18–60 years old) with confirmed HIV positive status, on combination ART (cART), and informed consent to participate. Participants with an acute medical illness or cognitive difficulties at the time of enrolment/administration of questionnaire or could not understand and/or communicate in the national language (Kiswahili), which was used during the administration of all study instruments, were excluded. A research team member introduced the study to eligible participants when they visited the clinic for scheduled appointments. Those who consented to take part responded to the instruments at the clinic.

Data collection procedures

Study data were collected and managed using Research Electronic Data Capture (REDCap) tools hosted at
The short version (HSS-12) of the Berger HSS\textsuperscript{14} was used to assess patient-perceived HIV-related stigma under four dimensions: (1) personalised stigma; (2) disclosure concerns; (3) negative self-image and (4) concerns with public attitudes, each comprising a subscale of the instrument. Personalised stigma has been suggested to represent the enacted stigma mechanism, disclosure concerns, and concerns with public attitudes dimensions have been proposed to represent anticipated stigma mechanism, and negative self-image has been proposed to represent internalised stigma mechanism.\textsuperscript{12} Items on this scale are rated from 1 to 4, with (1) being ‘strongly disagree’ and (4) ‘strongly agree.’ The possible score for each item ranges from 1 to 4 (3–12 for subscale), and a total score ranges between 12 and 48 and is derived from the summation of item scores. Higher scores designate a greater level of perceived HIV-related stigma.

**Patient Health Questionnaire version 9**

Patient Health Questionnaire version 9 (PHQ-9)\textsuperscript{11} was administered as a measure of depressive symptoms. The PHQ-9 is a nine-item scale rated on a Likert-type scale ranging from 0 ‘not at all’ to 3 ‘nearly every day.’ Item scores are summated to derive a total score ranging from 0 to 27. It has previously been found to have good internal consistency (Cronbach alpha 0.78) and acceptable test–retest reliability (intraclass correlation coefficient (ICC)=0.59) when used among adults living with HIV infection in Kenya.\textsuperscript{42}

**Generalised Anxiety Disorder version 7**

Generalised Anxiety Disorder version 7 (GAD-7)\textsuperscript{13} was administered as a clinical measure for assessing GAD based on the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria. The GAD-7 is a seven-item self-report instrument rated on a Likert-type scale ranging from 0 ‘not at all’ to 3 ‘nearly every day.’ The scale score ranges from 0 to 21. There is evidence in support of the reliability and validity of this scale in Kenya.\textsuperscript{41} Scores from PHQ-9 and GAD-7 were combined to generate a variable called symptoms of common mental disorders comorbidity, indicating the co-occurrence of depressive and anxiety symptoms.

**Sociodemographic and asset index items**

A sociodemographic questionnaire was used to collect information on the participants’ age, gender, relationship status, educational level, employment status and whom they currently shared a residence. Furthermore, an asset index previously used in this setting\textsuperscript{45} was used to collect information about participants’ socioeconomic status (SES) based on disposable assets owned. Participants were asked for ownership of disposable items such as radio, television, refrigerator, gas, bicycle, motorcycle and car. The final SES score had seven (7) items. A total asset score is calculated, and higher scores indicate a better SES. The maximum possible score for the asset index score was 7. An asset index to estimate family wealth has been recommended as an alternative approach to estimating SES in settings where reliable data on family income may not be available.\textsuperscript{46}

**Clinical information**

Participants’ data were extracted from the clinic’s medical record database and filled into a clinical record form. This information included participants’ dates of HIV-diagnosis, cART initiation, most current cART regimen, cluster of differentiation 4 (CD4) cell count, viral load (within the last 1 year), recent height and weight (for body mass index (BMI) calculation) and data on WHO clinical staging. Participants’ clinical information was retrieved from their clinical records after consent was granted. Patient-unique clinic numbers were used to access participants’ medical records. We report substantial missing
participant data on viral load from the database (n=145) with no follow-up record of CD4 cell count for all study participants.

**Instrument translation and cross-cultural adaptation**

The English version of the HSS-12 was forward translated by two independent bilingual translators to Kiswahili and back-translated into English by two independent back translators (oblivious of the original version). A group of Kenyan HIV researchers bilingual and fluent in both Kiswahili and English and the translators had a harmonisation meeting to review the content, conceptual, semantic and idiomatic equivalence of the questionnaires to ensure the cultural relevance of the HSS-12. Before conducting the formal phase of the study, 15 pretest interviews were conducted to assess instrument rigour and develop measures to address any limitations or threats to bias and management procedures. The final version of the questionnaire was obtained after the incorporation of changes emerging from pretesting. Pretesting procedures have been elaborated further elsewhere.

**Patient and public involvement**

Patients were not involved in the design and conduct of this study.

**Statistical analyses**

**Factor structure and measurement invariance across age groups and gender**

First, confirmatory factor analysis (CFA) was used to examine the HSS’s factor structure. A CFA model representing the Swahili version of the HSS-12 was set up and analysed with weighted least square mean and variance adjusted using the lavaan package in R statistical software on all the 450 observations. The Goodness of fit was assessed using the \( \chi^2 \) test, Comparative Fit Index (CFI), Tucker Lewis Index (TLI) and root mean square error of approximation (RMSEA). The data were expected to have a good fit to the model if the \( \chi^2 \) test was nonsignificant, CFI and TLI values were greater than 0.90, and RMSEA score was lower than 0.05.

Second, after defining the model, Multi-Group CFA was used to test for measurement invariance of the HSS-12 for gender and age groups. Change in CFI (\( \Delta \)CFI) has been suggested as a robust statistic for testing the between-group invariance of CFA models. Additionally, it has been recommended that invariance can be assumed when \( \Delta \)CFI is \( \leq 0.01 \) in absolute values.

**Internal construct validity and convergent validity**

Means and SD were used to evaluate the distribution of scores within the subscale and among the items. Itemised means and SD were expected to be almost the same within the subscale, justifying item scores’ aggregation into subscale scores. The item-total correlation was used to evaluate internal construct validity. Each items’ corrected item-total correlation coefficients were calculated and expected to exceed 0.4 and vary in range. Convergent validity was assessed using the Pearson correlation coefficient between HSS-12, PHQ-9, and GAD-7 scores. Correlation coefficients were interpreted as small (0.10–0.29), moderate (0.30–0.49) and large (0.49 and above).

**Reliability**

Cronbach’s alpha and ordinal alpha were used to examine each subscale’s internal consistency and overall scores of the Swahili version of the HSS-12. Cronbach’s alpha was considered acceptable if greater than (>0.7). The ICC was used to examine test–retest of the Swahili version of the HSS-12 by correlating scores taken at two different time points (2 weeks apart) using the same measure administered to the same participant. ICC of 0.60 was considered marginal, 0.70 acceptable and anything over 0.80 considered high.

**Sample characteristics and correlates**

Frequencies and means (with percentages and SD) were used to describe sample characteristics. Univariate and multivariable linear regression were used to assess factors associated with both stigma subscales and the overall stigma scale. In the regression model, stigma scores were expressed as a continuous measure. Independent variables included age, gender, marital status, education level, employment status, SES, BMI, viral load, WHO clinical stages, months since HIV diagnosis, months since cART initiation, HIV status disclosure, self-reported opportunistic infections, and the co-occurrence of depressive and anxiety symptoms. Our review of the literature informed factors included in the model. All variables with p<0.20 were included in the multivariable regression model apart from viral load because participants had missing values (n=145). The final multivariable models were generated using a backward stepwise approach by eliminating all variables independently with p>0.05. Assumptions of linear regression testing were visually inspected through histograms (linearity), normal probability plots (normality) and plots of residual vs predicted values (homoosedasticity). Multicollinearity was assessed using the variance inflation factor. There were no multicollinearity problems. Modelling was undertaken five times in total: once to predict overall stigma and once to predict each of the four subscales. R (V.4.0.2) statistical software package was used to explore the construct validity of the HSS-12. All other analyses were run using (Stata V.14.0) statistical software package.

**RESULTS**

**Sample characteristics**

The 450 participants had a median age of 43 years (IQR=36–50), ranging from 18 to 60 years. The vast majority of the sample were female (79.1%), had attained basic primary level education (53.1%), lived with a family member (82.4%) and were unemployed (59.8%). Less than half of the study participants (43.8%) were separated, divorced or widowed. The mean BMI was within the normal range (mean (SD)=22.4 (4.8)). Most study participants were not involved in the design and conduct of this study.
participants had disclosed their HIV status to others (94.0%). The median time since HIV diagnosis was 8.8 years (IQR=4.67–11.50), ranging from 0 to 18 years. A total of 417 (93.7%) were in stage 1 of the WHO clinical staging, and 425 (95.3%) were on the first-line cART regimen (table 1). The median time elapsed since cART initiation was 6.7 years (IQR=3.67–10.00). At the time of the interview, less than a fifth (18.4%) of the study participants had an opportunistic infection.

Perceived overall stigma scores ranged from 12 to 48, with a median score of 28 (IQR=23–33). Using PHQ-9 and GAD-7 cut-off score of ≥10, which has been shown to maximise specificity and sensitivity for depression and anxiety screening, the overall prevalence of depression and anxiety was 13.8% and 5.3%, respectively, among enrolled participants. The co-occurrence of depressive and anxiety symptoms was present in 4.7% of the study participants.

**Factor structure and measurement invariance across age groups and gender**

Online supplemental figure 1 presents CFA results with standardised correlation coefficients. Our hypothesised model that the overall stigma scale comprises four subscales correlated was confirmed given the observed fit indexes. The χ² test was statistically significant (χ²=91.982, df=50, p=0.000) but alternate fit measures indicated acceptable fit; RMSEA: 0.044; CFI:0.966 and TLI: 0.955. These results generally indicate that the data had a good fit to the model and that we can confidently use both total and subscale scores in this population. Measurement invariance across age groups and gender was supported because ΔCFIs are lower than 0.01 in all models suggesting that measurement invariance can be assumed.

**Internal construct validity and convergent validity**

The factor loading of all items on the hypothesised scale was good except for item 6 (0.21) under the disclosure concern subscale. Convergent validity of the HSS-12 was demonstrated by the small to moderate correlations between HSS-12 and the correlation with the following relevant measures: GAD-7 (r=0.368, p<0.001) and PHQ-9 (r=0.328, p<0.001) table 2.

**Reliability: internal consistency and test–retest**

Cronbach’s alpha (α) for the subscales and overall scale were all >0.7 (see table 2) except for the disclosure concern sub-scale, which was 0.53 (95% CI: 0.46 to 0.60). Additionally, ordinal α for the subscales ranged from 0.65 to 0.91. The test–retest reliability of the short 12-item version of the HSS was excellent, 0.92 (95% CI: 0.87 to 0.95). Additionally, table 2 presents descriptive statistics for the stigma scale on the item level and subscale level. Corrected item-total correlation coefficients were >0.4 for all the items except one item (0.21) in the disclosure concerns subscale. A variation of 0.46–0.88 indicates

| Table 1 | Participant’s sociodemographic characteristics |
|---------|-----------------------------------------------|
| Sample characteristics | Total sample |
| N=450 | % |
| **Sociodemographic characteristics** | | |
| Age—years range (18–60), median (IQR) | 43 (14) |
| Gender | | |
| Female | 356 | 79.1 |
| Male | 94 | 20.9 |
| Marital status | | |
| Married/cohabiting | 196 | 43.6 |
| Separated/divorced/widowed | 197 | 43.8 |
| Single/never married | 57 | 12.7 |
| Education | | |
| Tertiary | 22 | 4.9 |
| Secondary | 66 | 14.7 |
| Primary | 239 | 53.1 |
| None | 123 | 27.3 |
| Employment | | |
| Formally employed | 53 | 11.8 |
| Self-employed | 117 | 26.0 |
| Other | 11 | 2.4 |
| Unemployed (including students) | 269 | 59.8 |
| Currently living with | | |
| Family | 371 | 82.4 |
| Relative/friend | 10 | 2.2 |
| Alone | 69 | 15.3 |
| Asset index score*—mean (SD) | 1.2 (1.4) |
| Perceived HIV-stigma score†—mean (SD) | 28.4 (7.7) |
| Any current chronic illness | | |
| No | 413 | 91.8 |
| Yes | 37 | 8.2 |
| **Clinical characteristics** | | |
| BMI—kg/m², mean (SD), OM=4 | 22.4 (4.8) |
| cART regimen, OM=4 | | |
| First line | 425 | 95.3 |
| Second line | 21 | 4.7 |
| Viral load, OM=145 | | |
| ≤1000 copies/mL | 265 | 86.9 |
| >1000 copies/mL | 40 | 13.1 |
| WHO clinical stage, OM=5 | | |
| Stage 1 | 417 | 93.7 |
| Stage 2 | 22 | 4.9 |

Continued
level of education, being self-employed or unemployed, having a viral load of >1000 copies/mL, decreased duration since HIV diagnosis, decreased duration since cART initiation, having any current opportunistic infection and the co-occurrence of depressive and anxiety symptoms.

When a multiple linear regression model was run, it was found that being female (β=2.001, 95% CI: 0.21 to 3.80, p=0.029), HIV status disclosure (β=4.237, 95% CI: 1.27 to 7.20, p=0.005) and co-occurrence of depressive and anxiety symptoms (β=6.670, 95% CI: 3.40 to 9.94, p<0.001) were significant predictors of perceived HIV stigma. Having no education was associated with increasing stigma levels at p=0.051 (β=3.318, 95% CI: -0.01 to 6.65). Regression results indicated that the model explained 10.2% of the variance and that the model was a significant predictor of perceived HIV stigma (F(6, 395)=7.46, p<0.001).

Concerning the four subscales, we found that personalised stigma was positively correlated with being female and the co-occurrence of depressive and anxiety symptoms. Disclosure concern was inversely correlated with duration since HIV diagnosis and positively correlated with having no level of education and HIV status non-disclosure. Concerns with public attitudes were positively correlated with being female. Negative self-image was positively correlated with having no level of education and the co-occurrence of depressive and anxiety symptoms.

**DISCUSSION**

This cross-sectional analysis of data from adults living with HIV observed that the HSS-12 presents excellent psychometric properties. Additionally, we observed that stigma was associated with both physical and mental well-being. According to our study, correlates of HIV-related stigma include being female, HIV status non-disclosure, and the co-occurrence of depressive and anxiety symptoms.

**Factor structure, measurement invariance, validity and reliability of the short 12-item Swahili version of the HSS**

The study examined the stigma scale’s psychometric properties to assess its usefulness and describe the correlates of HIV-related stigma among adults living with HIV in Kilifi. Reliability and validity were acceptable, and CFA supported the four-factor solution measuring the four dimensions of HIV stigma. Cronbach’s alpha for the HSS-12 among the Kenyan population is similar to the Swedish population in which the scale was developed. Although Cronbach’s alpha for the adapted HSS-12 subscales was slightly lower (0.53–0.84) than the initial version of HSS-12 (0.80–0.88), its’ alpha for the total scale was 0.80 suggesting good internal consistency. Furthermore, the adapted HSS-12 had an ordinal alpha of 0.86. The difference between ordinal alpha and Cronbach’s alpha values could be attributed to high skewness and kurtosis values for some of the questionnaire’s questions, influencing Cronbach’s alpha estimate values.

Measurement invariance of the Swahili HSS-12 was evaluated and confirmed across main interest groups.
Table 2  Descriptive statistics for items and subscales in the short form 12-item Swahili version of the HIV stigma scale

| Item                                           | Mean item score† (SD) | Corrected item correlation | Mean subscale score‡ (SD) | Reliability                      | Validity               |
|-----------------------------------------------|-----------------------|-----------------------------|---------------------------|----------------------------------|------------------------|
|                                              |                       |                             |                           | Internal consistency (Cronbach α) | Convergent             |
|                                              |                       |                             |                           | Test–retest (ICC)                | Construct              |
|                                              |                       |                             |                           | §                               | ¶                       |
|                                              |                       |                             |                           | CFI, RMSEA, TLI                  |                        |
| Personalised stigma                          | 4.86 (2.56)           |                             | 0.84 (95% CI 0.81 to 0.86) | 0.83 (95% CI 0.71 to 0.90)       | 0.357* 0.327*          |
| Some people stop touching me soon they know/realise I am infected with HIV/AIDS. | 1.66 (1.01)           | 0.65                        |                           |                                 |                        |
| People I care for stopped calling me after knowing I suffer from AIDS.          | 1.63 (1.00)           | 0.87                        |                           |                                 |                        |
| I have lost friends for telling/explaining that I have AIDS.                   | 1.59 (0.96)           | 0.88                        |                           |                                 |                        |
| Disclosure concerns                      | 8.74 (2.37)           |                             | 0.53 (95% CI 0.45 to 0.60) | 0.62 (95% CI 0.36 to 0.77)       | 0.070 0.070           |
| Telling someone that I have AIDS is dangerous,† | 2.24 (1.24)           | 0.83                        |                           |                                 |                        |
| I do all I can to keep my AIDS (HIV) status secret.                          | 2.90 (1.22)           | 0.46                        |                           |                                 |                        |
| I am very careful to that person I tell about my HIV status (I am cautious/very careful to (?of) the people I tell my HIV status). | 3.60 (0.78)           | 0.21                        |                           |                                 |                        |
| Concerns about public attitudes             | 8.52 (3.17)           |                             | 0.83 (95% CI 0.80 to 0.88) | 0.79 (95% CI 0.65 to 0.88)       | 0.187* 0.165*          |
| People who are suffering from AIDS are treated as if they are not like the other people. | 3.05 (1.18)           | 0.68                        |                           |                                 |                        |
| People believe that a person infected with HIV is dirty.                     | 2.74 (1.26)           | 0.84                        |                           |                                 |                        |
| Many people are worried when they are near a person infected with HIV.        | 2.75 (1.22)           | 0.84                        |                           |                                 |                        |
| Negative self-image                        | 6.32 (3.00)           |                             | 0.74 (95% CI 0.70 to 0.80) | 0.76 (95% CI 0.60 to 0.86)       | 0.372* 0.330*          |
| I feel guilty because I am infected with HIV.                                 | 2.11 (1.23)           | 0.60                        |                           |                                 |                        |
| People’s attitudes about HIV/AIDS makes me feel very bad.                    | 2.23 (1.25)           | 0.78                        |                           |                                 |                        |
| I feel I am not as good as others because I’m infected with HIV.              | 2.01 (1.23)           | 0.73                        |                           |                                 |                        |
| Overall                                   | 28.44 (7.68)          |                             | 0.80 (95% CI 0.77 to 0.83) | 0.92 (95% CI 0.87 to 0.95)       | 0.368* 0.328* 0.966 0.044 0.955 |

Pearson product-moment correlation coefficient.  
*p<0.001  †Possible score for each item 1–4; higher scores reflect a higher level of perceived HIV-related stigma  
‡Possible score 3–12 on each sub-scale; higher scores reflect a higher level of perceived HIV-related stigma.  
§Correlation between HIV stigma and GAD-7.  
¶Correlation between HIV stigma and PHQ-9.  
CFI, Comparative Fit Index; Cronbach α, Cronbach alpha; RMSEA, root mean square error of approximation; SD, Standard Deviation; TU, Tucker Lewis Index.
Table 3  Univariate linear regression of correlates of perceived HIV-related stigma among adults living with HIV from rural Kilifi

| Independent variables | N  | Personalised stigma B (95% CI) | Disclosure concerns B (95% CI) | Public attitudes B (95% CI) | Negative self-image B (95% CI) | Overall HIV stigma score‡ B (95% CI) |
|-----------------------|----|--------------------------------|-----------------------------|-----------------------------|-------------------------------|-----------------------------------|
| Sociodemographic characteristics |     |                                |                             |                             |                               |                                   |
| Age                   | 450 | −0.01 (−0.03 to 0.02)          | 0.01 (−0.02 to 0.02)        | 0.01 (−0.02 to 0.04)        | 0.01 (−0.03 to 0.03)          | 0.01 (−0.07 to 0.08)              |
| Gender                | 450 |                               |                             |                             |                               |                                   |
| Male                  |     | Ref (Ref)                      | Ref (Ref)                   | Ref (Ref)                   | Ref (Ref)                     | Ref (Ref)                        |
| Female                | 0.52 (−0.06 to 1.10) | 0.080* | 0.29 (−0.25 to 0.83) | 1.07 (0.35 to 1.79) | 0.003** | 0.40 (−0.29 to 1.08) | 0.255 | 2.27 (0.54 to 4.01) | 0.010** |
| Marital status        | 450 | 0.074                          |                             |                             |                               |                                   |
| Married               |     | Ref (Ref)                      | Ref (Ref)                   | Ref (Ref)                   | Ref (Ref)                     | Ref (Ref)                        |
| Separated/divorced/widowed | 0.54 (0.03 to 1.04) | 0.038** | 0.67 (0.20 to 1.14) | 0.005** | 0.25 (−0.38 to 0.87) | 0.442 | 0.73 (0.14 to 1.32) | 0.016** | 2.18 (0.67 to 3.69) | 0.005** |
| Single/never married  | 0.61 (−0.14 to 1.37) | 0.111** | 0.17 (−0.52 to 0.87) | 0.626 | −0.43 (−1.37 to −0.51) | 0.369 | 0.40 (−0.49 to 1.28) | 0.378 | 0.75 (−1.50 to 3.01) | 0.512 |
| Education level       | 450 |                               |                             |                             |                               |                                   |
| Tertiary              |     | Ref (Ref)                      | Ref (Ref)                   | Ref (Ref)                   | Ref (Ref)                     | Ref (Ref)                        |
| Secondary             | −0.12 (−1.36 to 1.12) | 0.847 | 0.08 (−1.06 to 1.21) | 0.896 | 0.68 (−0.84 to 2.21) | 0.380 | −0.03 (−1.46 to 1.40) | 0.967 | 0.61 (−3.05 to 4.26) | 0.745 |
| Primary               | −0.31 (−1.43 to 0.81) | 0.582 | 0.48 (−0.55 to 1.51) | 0.360 | 1.32 (−0.06 to 2.70) | 0.061* | 0.72 (−0.57 to 2.01) | 0.273 | 2.20 (−1.10 to 5.51) | 0.191* |
| None                  | 0.15 (−1.01 to 1.32) | 0.794 | 1.23 (0.16 to 2.30) | 0.024** | 1.80 (0.36 to 3.23) | 0.014** | 1.63 (0.29 to 2.97) | 0.018** | 4.81 (1.38 to 8.25) | 0.006** |
| Employment status     | 450 |                               |                             |                             |                               |                                   |
| Formally employed     |     | Ref (Ref)                      | Ref (Ref)                   | Ref (Ref)                   | Ref (Ref)                     | Ref (Ref)                        |
| Self-employed         | 0.67 (−0.16 to 1.50) | 0.112* | 0.27 (−0.50 to 1.05) | 0.490 | 0.46 (−0.57 to 1.49) | 0.385 | 0.73 (−0.24 to 1.70) | 0.141* | 2.13 (−0.36 to 4.62) | 0.094* |
| Other                 | −0.67 (−2.33 to 0.99) | 0.429 | −0.02 (−1.57 to 1.53) | 0.983 | −1.14 (−3.20 to 0.93) | 0.279 | −0.35 (−2.29 to 1.60) | 0.726 | −2.17 (−7.15 to 2.81) | 0.392 |
| Unemployed            | 0.51 (−0.25 to 1.26) | 0.187* | 0.33 (−0.37 to 1.03) | 0.360 | 0.18 (−0.76 to 1.11) | 0.710 | 1.03 (0.15 to 1.91) | 0.022* | 2.04 (−0.22 to 4.30) | 0.077* |
| Currently living with | 450 |                               |                             |                             |                               |                                   |
| Immediate family      |     | Ref (Ref)                      | Ref (Ref)                   | Ref (Ref)                   | Ref (Ref)                     | Ref (Ref)                        |
| Relative/friend       | 0.86 (−0.75 to 2.47) | 0.294 | 0.02 (−1.47 to 1.52) | 0.975 | 0.18 (−1.82 to 2.18) | 0.862 | −0.45 (−2.34 to 1.45) | 0.644 | 0.62 (−4.23 to 5.46) | 0.802 |
| Alone                 | 0.01 (−0.65 to 0.66) | 0.995 | −0.25 (−0.87 to 0.36) | 0.414 | −0.06 (−0.88 to 0.76) | 0.887 | −0.07 (−0.84 to 0.70) | 0.860 | −0.38 (−2.36 to 1.60) | 0.706 |
| Asset index score—mean (SD) | −0.12 (−0.29 to 0.05) | 0.171* | −0.13 (−0.29 to 0.03) | 0.109* | −0.11 (−0.33 to −0.10) | 0.310 | −0.12 (−0.32 to −0.08) | 0.244* | −0.48 (−1.00 to −0.04) | 0.068* |
| Clinical characteristics |     |                               |                             |                             |                               |                                   |
| BMI—kg/m²; mean (SD); OM=4 | 0.004 (−0.04 to 0.06) | 0.855 | −0.03 (−0.07 to 0.02) | 0.244 | 0.03 (−0.03 to 0.09) | 0.309 | −0.03 (−0.18 to 0.12) | 0.708 | −0.03 (−0.18 to 0.12) | 0.708 |
| Viral load OM=145     | 305 |                               |                             |                             |                               |                                   |
| ≤1000 copies/mL       |     | Ref (Ref)                      | Ref (Ref)                   | Ref (Ref)                   | Ref (Ref)                     | Ref (Ref)                        |
| >1000 copies/mL       | 0.58 (−0.28 to 1.44) | 0.183* | 0.10 (−0.70 to 0.90) | 0.07 (−1.00 to 1.14) | 0.894 | 1.05 (0.08 to 2.02) | 0.033** | 1.81 (−0.79 to 4.40) | 0.172* |
| Months since HIV diagnosis | 450 | 0.00 (−0.00 to 0.01) | 0.346 | −0.01 (−0.01 to −0.00) | 0.001** | −0.00 (−0.01 to 0.00) | 0.630 | −0.01 (−0.01 to 0.00) | 0.057* | −0.01 (−0.03 to 0.00) | 0.091* |
| Months since cART initiation OM=4 | 446 | 0.00 (−0.00 to 0.01) | 0.497 | −0.01 (−0.01 to −0.00) | 0.001*** | −0.00 (−0.01 to 0.00) | 0.202* | −0.01 (−0.01 to −0.00) | 0.031** | −0.02 (−0.03 to −0.00) | 0.031** |
| Treatment characteristics |     |                               |                             |                             |                               |                                   |
| Yes                   | 450 | Ref (Ref)                      | Ref (Ref)                   | Ref (Ref)                   | Ref (Ref)                     | Ref (Ref)                        |
| Continued
gender and age. Our results indicated that the measurement model of the Swahili HSS-12 as a patient-reported outcome to measure perceived HIV stigma among adults is comparable across age groups and gender (table 5).

Test–retest reliability, an indicator of scale stability over time, was of acceptable levels. The original HSS-40 has been used in diverse settings among adults 18 years and above, reporting a test retest reliability between (ICC=0.89–0.92). To the best of our knowledge, no study has reported the test retest reliability of the HSS-12.

We examined the construct validity of the scale using CFA since its hypothesised structure has been published. Our results indicated that the hypothesised model fit the data well and was almost similar to what was reported by a study conducted in Sweden. These results indicate that one can use both the total scores and the subscale scores and interpret the results in confidence, knowing that the items fit well together. HSS-12 evidenced convergent validity by being correlated with PHQ-9, a measure of depression and GAD-7, a measure of anxiety in conventional ways.

The HSS-12 was reliable and valid for detecting stigma among adults living with HIV at the Kenyan Coast. Consequently, HSS-12 can be practically used as a brief screening tool for stigma-related problems both for research and clinical purposes. Future research could examine its predictive validity and evaluate its sensitivity to changes. This information would be crucial in determining its usefulness as an evaluation tool for programmes and interventions.

**Correlates of stigma**

Being female was positively associated with increased perceived HIV-related stigma scores, personalised stigma, and concern with public attitudes. This finding agrees with previous studies from SSA and outside that reported a positive association between female gender and perceived HIV-related stigma. Research shows that females are more likely to suffer from stigma in patriarchal societies like Kenya than males. Research has established that the African society is less tolerant of females living with HIV than males living with HIV. Due to women’s subordinate status in society, they are often stigmatised as vectors of transmission. Furthermore, the common belief that HIV is caused by indecent sexual behaviour has worse societal consequences for women who are expected to be monogamous, unlike men in most African societies. Women are often blamed counterfactually to be responsible for HIV transmission. Similar processes can be assumed to be at work in the Kenyan coastal region.

HIV status disclosure was positively associated with overall HIV-related stigma scores and disclosure concerns, with persons who had not disclosed their HIV status reporting greater levels of concern about HIV disclosure concerns. Anakwa et al found that PLWHA with higher levels of perceived HIV-related stigma reported greater levels of HIV disclosure concerns; therefore, they are less likely to disclose...
Table 4  Multivariate linear regression of correlates of perceived HIV-related stigma among adults living with HIV from rural Kilifi

| Independent variables | Personalised stigma (n=402) | Disclosure concerns (n=450) | Public attitudes (n=450) | Negative self-image (n=402) | Overall HIV Stigma Score (n=402) |
|----------------------|-----------------------------|-----------------------------|--------------------------|----------------------------|---------------------------------|
|                      | B (95% CI)                  | B (95% CI)                  | B (95% CI)               | B (95% CI)                 | B (95% CI)                     |
|                      | P value                     | P value                     | P value                  | P value                    | P value                         |
| Sociodemographic characteristics |
| Gender                |                             |                             |                          |                            |                                 |
| Male                  | Ref                         | Ref                         | Ref                      | Ref                        |                                 |
| Female                | 0.75 (0.17 to 1.34)         | 1.07 (0.35 to 1.79)         | 2.00 (0.21 to 3.80)      | 0.029**                    |
|                      | 0.012**                     | 0.003**                     | 0.029**                  |                            |                                 |
| Education level       |                             |                             |                          |                            |                                 |
| Tertiary              | Ref                         | Ref                         | Ref                      | Ref                        |                                 |
| Secondary             | −0.04 (−1.14 to 1.07)       | 0.950                       | −0.34 (−3.83 to 3.16)    | 0.850                      |
| Primary               | 0.48 (−0.52 to 1.48)        | 0.346                       | 1.37 (−1.75 to 4.50)     | 0.388                      |
| None                  | 1.24 (0.20 to 2.28)         | 0.019**                     | 3.32 (−0.01 to 6.65)     | 0.051                      |
| Clinical characteristics |
| Months since HIV diagnosis | −0.01 (−0.01 to 0.00)       | 0.007**                     |                          |                            |
| Treatment characteristics |
| HIV status disclosure |                             |                             |                          |                            |                                 |
| Yes                   | Ref                         | Ref                         | Ref                      | Ref                        |                                 |
| No                    | 1.79 (0.88 to 2.70)         | 0.000**                     | 4.24 (1.27 to 7.20)      | 0.005**                    |
| CMD comorbidity       |                             |                             |                          |                            |                                 |
| Absence               | Ref                         | Ref                         | Ref                      | Ref                        |                                 |
| Presence              | 2.67 (1.55 to 3.79)         | 0.000**                     | 6.67 (3.40 to 9.94)      | 0.000**                    |
| Variance explained by the model | Pseudo R-squared | 6.76%                       | 8.66%                    | 10.17%                     |

Overall stigma scale represents the sum of all twelve items from the four subscales.

**P<0.05, ***p<0.001.

CI, Confidence Interval; CMD, symptoms of depression and anxiety; Ref, Reference category.
their status. From our study, only 6% had not disclosed their status to anyone. HIV status non-disclosure might be a protective behaviour for PLWHA to conceal their status, evade adverse reactions towards themselves, weigh other people’s reactions, and as a sign of concern about the implications of their disclosure on their disclosure targets.70 71 Furthermore, disclosure entails deciding how and to whom to disclose and identifying appropriate opportunities to disclose or devising means to conceal one’s status and/or medication in order to improve access and adherence to their treatment regimen.

The co-occurrence of depressive and anxiety symptoms was positively correlated with overall HIV-related stigma scores, personalised stigma and negative self-image. This finding corroborates previous studies among PLWHA carried out within SSA26 30 72 and outside,73 74 which have invariably found a significant association between HIV-related stigma and depressive symptoms. Liu et al25 reported that the more stigma PLWHA perceived, the more anxiety they experienced. Similarly, we report that HIV-related stigma is significantly associated with the co-occurrence of depressive and anxiety symptoms. Additionally, an individual’s perception of themselves in light of their diagnosis appears to trigger depression. Screening for depression, anxiety and HIV-related stigma might provide insights on interventions that may promote a positive attitude and self-image, thereby reducing depression, anxiety and stigma, leading to psychological and physical well-being. Given the cross-sectional nature of the study, we cannot claim causality. However, the association between co-occurrence of depressive and anxiety symptoms and stigma provides the impetus for: (1) longitudinal studies to elucidate causal pathways and (2) targeted interventions to address both stigma and mental health to improve health outcomes of adults living with HIV.

Other factors influencing the four subscales were also established. Having no level of education was positively associated with higher reported disclosure concerns and negative self-image, corroborating findings of studies carried out in Nigeria77 and the USA.78 Lower levels of education may lead to less exposure, lack of or little knowledge about HIV infection and transmission. In contrast, higher levels of education might lead to higher levels of knowledge, providing exposure to new ways of thinking and new sources of information about the HIV pandemic resulting in the reduction of less supportive attitudes towards PLWHA.79 80 Previous research has demonstrated that people with high levels of knowledge of the transmission routes for HIV consistently had more supportive attitudes towards those with HIV demonstrating the role that knowledge has in reducing the misconceptions that act to create fear and shape stigma.79

Months since HIV diagnosis was inversely associated with disclosure concerns, with persons with a more recent diagnosis reporting greater levels of concern about HIV status disclosure. This is consistent with a study of PLWHA in China81 and among African Americans.79 This finding suggests that living longer with HIV is associated with positive outcomes because PLWHA are likely to adjust over time to their HIV positive status, receive more information, develop greater insights and understanding of the disease and establish psychological mechanisms to better cope with HIV stigma leading to lower levels of perceived HIV stigma.

Strengths and limitations of this study

A potential strength is that this is the first study to report the measurement characteristics of the HSS-12 in the SSA context. We recognise several potential limitations in this study. First, the study was in a clinical setting where our study sample consisted of adults living with HIV on cART. Compared with untreated individuals living with HIV, it is likely that levels of HIV stigma would be lower in our sample because it has been shown that access to ART lowers stigma.82 84 Second, this study is cross-sectional, so causality for the observed significant associations cannot be inferred. We can also not conclude how individuals may experience stigma over time because of the study design limitation. Third, findings may not be generalisable to all adults living with HIV in Kenya as data were collected from one geographical setting and excluded adults

### Table 5 Multigroup confirmatory factor analysis for age and gender subgroups

| Invariance steps | Gender | RMSEA | TLI | CFI | ΔCFI | Age         | RMSEA | TLI | CFI | ΔCFI |
|------------------|--------|-------|-----|-----|------|-------------|-------|-----|-----|------|
| Configural       | Female | 0.051 | 0.934 | 0.950 | 0.007 | Older adults | 0.040 | 0.960 | 0.970 | 0.003 |
|                  | Male   | 0.051 | 0.934 | 0.950 | 0.007 | Young adults | 0.040 | 0.960 | 0.970 | 0.003 |
| Metric invariance| Female | 0.052 | 0.932 | 0.943 | 0.007 | Older adults | 0.042 | 0.957 | 0.964 | 0.006 |
|                  | Male   | 0.052 | 0.932 | 0.943 | 0.007 | Young adults | 0.042 | 0.957 | 0.964 | 0.006 |
| Scalar invariance| Female | 0.050 | 0.936 | 0.943 | 0.000 | Older adults | 0.041 | 0.959 | 0.963 | 0.001 |
|                  | Male   | 0.050 | 0.936 | 0.943 | 0.000 | Young adults | 0.041 | 0.959 | 0.963 | 0.001 |
| Strict invariance| Female | 0.048 | 0.941 | 0.942 | 0.001 | Older adults | 0.041 | 0.959 | 0.960 | 0.003 |
|                  | Male   | 0.048 | 0.941 | 0.942 | 0.001 | Young adults | 0.041 | 0.959 | 0.960 | 0.003 |

Criteria for an acceptable fit were a RMSEA of <0.06, and a CFI, and a TLI of ≥0.90. Configural invariance—no constraints; Full metric invariance—with all factor loadings constrained equal. Scalar invariance—with all intercepts constrained equal; Strict invariance—with all factor loadings and intercepts fixed; Measurement invariance is assumed when ΔCFI is ≤0.01.

CFI, Comparative Fit Index; RMSEA, root mean square error of approximation; TLI, Tucker-Lewis Index.
older than 60 years. Fourth, because many participants (n = 145) lacked information on their most recent viral load and none had follow-up data on CD4 counts, these variables were excluded from the regression analyses. A disproportionately large number of patients, combined with financial constraints, may explain why these tests are not routinely performed. Future studies, particularly those from resource-constrained settings, should budget for these tests because these biological factors have been associated with HIV-related stigma. Finally, the psychometric robustness of the disclosure concern subscale may be limited. We recommend further research into investigating this specific subscale.

Conclusions and implications
From the study, the 12-item short version of the Berger HS14 had good psychometric properties and can be recommended for research purposes. The current study suggests that women, those who have not disclosed, and those experiencing co-occurring depressive and anxiety symptoms experience a higher level of perceived HIV stigma in Coastal Kenya. This finding is useful in designing future interventions to improve the quality of life of PLWHA. We propose interventions that need to take into account gender to address the specific needs of women, people who have not disclosed their HIV status, and those exhibiting symptoms of depression and anxiety, thereby improving their quality of life. All these interventions will help in bettering both the physical and mental well-being of adults living with HIV. Additionally, it would be prudent to investigate further the association between lower education and HIV-related stigma as we found a marginal association.

Author affiliations
1Department of Public Health and Primary Care, Faculty of Medicine and Health Sciences Ghent University, Ghent, Belgium
2Department of Social Sciences, School of Humanities and Social Sciences Pwani University, Kilifi, Kenya
3Department of Clinical Research (Neurosciences), KEMRI/Wellcome Trust Research Programme, Centre for Geographic Medicine Research (Coast), Kilifi, Kenya
4Department of Clinical, Neuro- and Developmental Psychology, Amsterdam Public Health Research Institute, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
5Institute for Human Development, The Aga Khan University, Nairobi, Kenya
6Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia
7Department of Psychiatry, Oxford University, Oxford, UK
8Department of Public Health, Pwani University, Kilifi, Kenya

Twitter Stanley W Wanjala @Stan_wanjala and Moses K Nyongesa @CHAMZMK

Acknowledgements
We thank our participants for taking the time and effort to participate in this study and the Comprehensive Care and Research Centre (CCRC) staff in the Kilifi County Hospital HIV care and treatment clinic for their unrelenting support. We appreciate Patrick Katana Vidzo for helping with the entry of clinical data. The authors acknowledge the Kenya Medical Research Institute (KEMRI) Director for permission to publish this work.

Contributors SWW, CRJCN and AA conceptualised the study. SWW, MKN and AA designed the study. PM formulated study questions for tablet administration and managed the data. SWW and MKN supervised data collection. SWW, MKK, and AMM participated in data collection. SWW and MKN analysed the data. SWW, MKN, PM, AMM, SL, CRJCN and AA contributed to interpreting the data. SWW wrote the first draft of the manuscript. All authors reviewed subsequent versions of the manuscript and approved the final version for submission. The corresponding author affirms that all listed authors meet authorship criteria and that no other author meeting the criteria has been omitted. As guarantor, AA accepts full responsibility for the conduct of the study, had access to the data, and controlled the decision to publish.

Funding
This work was supported by funding from the Medical Research Council (Grant number MR/M025454/1) to AA. This award is jointly funded by the UK Medical Research Council (MRC) and the UK Department for International Development (DFID) under the MRC/DFID concordant agreement and is also part of the EDCTP2 programme supported by the European Union.

Disclaimer
The funders had no role in the design, collection, analysis, interpretation and manuscript writing.

Competing interests
None declared.

Patient consent for publication
Not applicable.

Ethics approval
This study involves human participants and was approved by The local institutional review board, Scientific and Ethics Review Board (SERU; Ref KEMRI/SERU/CMMR/C/108/3594), granted ethical approval to recruit participants into the study. We obtained authorisation to work in the HIV care and treatment clinic from the Ministry of Health, County government of Kilifi (Ref HP/KCHS/VOL-VII/65). Study participants provided written, informed consent to be part of the study. Participants gave informed consent to participate in the study before taking part.

Provenance and peer review
Not commissioned; externally peer reviewed.

Data availability statement
Data are available on reasonable request. No additional data are available. Anyone interested in accessing the data reported in this article is free to write to the Data Governance Committee of the KEMRI Wellcome Trust Research Programme, review the application and advise as appropriate, and ensure that uses are compatible with the consent obtained from participants for data collection. Requests can be sent to the coordinator of the Data Governance Committee using the following email: dgc@kemri-wellcome.org.

Supplemental material
This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access
This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: http://creativecommons.org/licenses/by/4.0/.

ORCID iDs
Stanley W Wanjala http://orcid.org/0000-0003-1422-0162
Moses K Nyongesa http://orcid.org/0000-0002-7761-0718

REFERENCES
1 Joint United Nations Programme on HIV/AIDS. Global HIV & AIDS statistics — 2020 fact sheet. Available: https://www.unaids.org/en/resources/fact-sheet [Accessed 22 Feb 2021].
2 Joint United Nations Programme on HIV/AIDS. UNAIDS data 2020. Switzerland: UNAIDS, 2020. https://www.unaids.org/sites/default/files/media_asset/2020_aids-data-book_en.pdf
3 National AIDS Control Council (NACC). Kenya AIDS response progress report 2014: progress towards zero. Nairobi, Kenya: National AIDS Control Council of Kenya, 2014. https://www.unaids.org/sites/default/files/country/documents/KEN_narrative_report_2014.pdf
4 Stigma GE. Notes on the management of spoiled identity. New York: Simon and Shuster Inc, 1963.
5 Jones EE, Farina A, Hastorf AH. Social stigma: the psychology of marked relationships. New York: W.H. Freeman, 1984.
6 Maluccio JA, Wu F, Rokon RB, et al. Assessing the impact of food assistance on stigma among people living with HIV in Uganda using the HIV/AIDS stigma Instrument-PLWA (HASI-P). AIDS Behav 2017;21:766–82.
Dahlui M, Azanah N, Buliga A, et al. HIV/AIDS related stigma and discrimination against PLWHA in Nigerian population. *PLoS One* 2015;10:e014379.

Toth S, A York J, DePinto N. HIV stigma: perceptions from HIV-positive and HIV-negative patients in a community dental clinic. *J Dent Res Dent Clin Dent Prospects* 2016;10:263–9.

Nybлад L, Stangl A, Weiss E, et al. Combating HIV stigma in health care settings: what works? *J Int AIDS Soc* 2009;12:15.

Clark HJ, Lindner G, Armstead L. Stigma, disclosure, and psychological functioning among HIV-infected and non-infected African-American women. *Women & Health* 2004;38:57–71.

Lindberg MH, Wettergren L, Wiklander M, et al. Psychometric evaluation of the HIV stigma scale in a Swedish context. *PLoS One* 2014;9:e114867.

Gunmaw VA, Chaudori SR. From conceptualizing to measuring HIV stigma: a review of HIV stigma mechanism measures. *AIDS Behav* 2009;13:1160–77.

Berger BE, Ferrans CE, Lashley FR. Measuring stigma in people with HIV: psychometric assessment of the HIV stigma scale. *Res Nurs Health* 2001;24:518–29.

Reinious M, Wettergren L, Wiklander M, et al. Development of a 12-item short version of the HIV stigma scale. *Health Qual Life Outcomes* 2017;15:115.

Kinger C, Reece M, Obeng S, et al. Psychometric evaluation of a cross-culturally adapted felt stigma questionnaire among people living with HIV in Kenya. *AIDS Patient Care STDS* 2013;27:481–8.

Wiklander M, Rydström L-L, Ygge B-M, et al. Psychometric properties of a short version of the HIV stigma scale, adapted for children with HIV infection. *Health Qual Life Outcomes* 2013;11:195.

Holzemer WL, Uys LR, Chiwra ML. Validation of the HIV/AIDS stigma Instrument—PLWA (HASI-P) 2007;19:1002–12.

Bauman L, Silver E. Camacho S. Stigma among mothers with HIV/AIDS living with HIV in Kenya. *AIDS Care* 2015;27:520–8.

Bunn JY, Ellett GN, Rothenberg K. Stigma among patients attending art center of a tertiary care center for children with HIV infection. *AIDS Patient Care STDS* 2012;26:330–8.

Anakwa NO, Teye-Kwadjo E, Ketchch IA. Effect of HIV-related stigma and HIV-related stress on HIV disclosure concerns: a study of HIV-positive persons on antiretroviral therapy at two urban hospitals in Ghana. *Applied Research in Quality of Life* 2020:1–16.

Scott JAG, Bauni E, Moisi JC, et al. Profile: the Kilifi health and demographic surveillance system (KHDDS). *Int J Epidemiol* 2018;47:906–16.

Ngugi E, Kipruto S, Samozi P. Exploring Kenya’s inequality: iulling apart or pooling together? Kilifi County, Nairobi, Kenya: Kenya National Bureau of Statistics (KNBS) and the Society for International Development (SID), 2013.

Commission on Revenue Allocation (CRA). *Kenya County fact sheets*. 2011. Available: http://siteresources.worldbank.org/INTAFRICA/Resources/257994-1335471959878/Kenya_County_Fact_Sheets_Dec2011.pdf [Accessed 22 Aug 2018].

National AIDS Control Council. *Kenya HIV county profiles - 2016*. National AIDS Control Council, 2016: 49–52. http://nacc.or.ke/wp-content/uploads/2016/12/Kenya-County-Profiles-2016.pdf

Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: building an international community of software platform partners. *J Biomed Inform* 2019;55:103208.

Harris PA, Taylor R, Thielke R. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support 2009;42:377–81.

Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study, primary care evaluation of mental disorders. patient health questionnaire. *JAMA* 1999:282:1737–44.

Monahan PO, Schacham E, Reece M, et al. Validity/reliability of PHQ-9 and PHQ-2 depression scales among adults living with HIV/AIDS in Western Kenya. *J Gen Intern Med* 2009;24:189–97.

Spitzer RL, Kroenke K, Williams JBW, et al. A brief measure for assessing generalized anxiety disorder: the GAD-7. *Arch Intern Med* 2006;166:1092–7.

Osborn TL, Venturo-Conerly KE, Wasil AR. Depression and anxiety symptoms, social support, and demographic factors among Kenyan high school students. *J Child Fam Stud* 2019:1–12.

Nyongesa MK, Mwangai PN, Mwangi P, et al. Neurocognitive and mental health outcomes and association with quality of life among adults living with HIV: a cross-sectional focus on a low-literacy population from coastal Kenya. *BMJ Open* 2018;8:e023914.

Filmer D, LHJD P. Estimating wealth effects without expenditure data—or tears: an application to educational enrollments in states of India. *J Demography* 2001:38:115–32.

Nyongesa MK, Mwangi P, Wanjalwa SW, et al. Correlates of health-related quality of life among adults receiving combination antiretroviral therapy in coastal Kenya. *Health Qual Life Outcomes* 2020;18:1–14.

Rosseel Y. Lavaan: an R package for structural equation modeling and more. version 0.5–12 (BETA). *J Stat Softw* 2012;48:1–36.

R Core Team. R: a language and environment for statistical computing. *R Foundation for Statistical Computing*. [computer program] College Station, TX; StataCorp LP 2015.

Blunch N. Introduction to structural equation modeling using IBM SPSS statistics and AMOS. Sage, 2012.

van de Schoot R, Lugtig P, Hox J. A checklist for testing data quality, scaling assumptions, and reliability: the IQOLA project approach. *PLoS One* 2012;7:e48692.

Cheung GW, Renvold RB. Assessing extreme and acquiescence response sets in cross-cultural research using structural equations modeling. *J Cross Cult Psychol* 2000;31:187–212.

Ware Jr JE, BJJoce G. Methods for testing data quality, scaling assumptions, and reliability: the IQOLA project approach 1998:51:945–52.

Cohen J. *Statistical power analysis for the behavioural sciences*. 2nd edn. Hillsdale, NJ: L Erlbaum Associates, 1988.

Tabachnick B, Fidell L. Using multivariate statistics. 6th edn. Boston, É.-U.: U. Pearson, 2013.

Terwee CB, Bot SDM, de Boer MR, et al. Quality criteria were proposed for measurement properties of health status questionnaires. *J Clin Epidemiol* 2007;60:34–42.

Streiner DL. A checklist for evaluating the usefulness of rating scales. *Can J Psychiatry* 1993:38:140–8.

StataCorp LP. Stata statistical software: release 14. [computer program] College Station, TX; StataCorp LP 2015.

Akena D, Joska J, Obuku EA, et al. Sensitivity and specificity of clinician administered screening instruments in detecting depression among HIV-positive individuals in Uganda. *AIDS Care* 2013;25:1245–52.

Gardemann A, Guhn M, Zumbo B. Estimating ordinal reliability for Likert-type and ordinal item response data: a conceptual, empirical, and practical guide. *P Ass, Re & Evalu* 2012:17:1–13.

Wanjala SW, et al. *BMJ Open* 2022;12:e050709. doi:10.1136/bmjopen-2021-050709
González J, MJRP P. Cálculo E Interpretación del alfa de Cálculo E interpretación del alfa de Cronbach para el caso de validación de la consistencia interna de un cuestionario. Con DOS posibles escalas tipo Likert 2015;2:62–77.

Jeyaseelan L, Kumar S, Mohanraj R, et al. Assessing HIV/AIDS stigma in South India: validation and abridgement of the Berger HIV stigma scale. *AIDS Behav* 2013;17:434–43.

Nattabi B, Li J, Thompson SC, et al. Factors associated with perceived stigma among people living with HIV/AIDS in post-conflict Northern Uganda. *AIDS Educ Prev* 2011;23:193–205.

Swendeman D, Rotheram-Borus MJ, Comulada S, et al. Predictors of HIV-related stigma among young people living with HIV. *Health Psychol* 2006;25:501–9.

Asiedu GB, Myers-Bowman KS. Gender differences in the experiences of HIV/AIDS-related stigma: a qualitative study in Ghana. *Health Care Women Int* 2014;35:703–27.

Mugoya GCT, Ernst K. Gender differences in HIV-related stigma in Kenya. *AIDS Care* 2014;26:206–13.

Mbonu NC, van den Borne B, De Vries NK. Stigma of people with HIV/AIDS in sub-Saharan Africa: a literature review. *J Trop Med* 2009;2009:145891.

Amuyunzu-Nyamongo M, Okeng’o L, Wagura A, et al. Putting on a brave face: the experiences of women living with HIV and AIDS in informal settlements of Nairobi, Kenya. *AIDS Care* 2007;19:S25–34.

Muyinda H, Seeley J, Pickering H. Social aspects of AIDS-related stigma in rural Uganda 1997;3:143–7.

Linda P. To tell or not to tell: negotiating disclosure for people living with HIV on antiretroviral treatment in a South African setting. *Sahara J* 2013;10:S17–27.

Evangelí M, Wroe AL. HIV disclosure anxiety: a systematic review and theoretical synthesis. *AIDS Behav* 2017;21:1–11.

Nyongesa MK, Mwangi P, Wanjala SW, et al. Prevalence and correlates of depressive symptoms among adults living with HIV in rural Kilifi, Kenya. *BMC Psychiatry* 2019;19:333.

Charles B, Jeyaseelan L, Pandian AK. Association between stigma, depression and quality of life of people living with HIV/AIDS (PLHA) in South India—a community based cross sectional study 2012;12:463.

Yi S, Chhou P, Suong S, et al. AIDS-related stigma and mental disorders among people living with HIV: a cross-sectional study in Cambodia. *PLOS One* 2015;10:e0121461.

Liu Y, Gong H, Yang G. Perceived stigma, mental health and unsafe sexual behaviors of people living with HIV/AIDS 2014;39:658–63.

Onyebuchi-Iwuombia O, Brown A. HIV and depression in Eastern Nigeria: the role of HIV-related stigma. *AIDS Care* 2014;26:653–7.

Oke OO, Akinbora AO, Olanrewaju FO, et al. Assessment of HIV-related stigma and determinants among people living with HIV/AIDS in Abeokuta, Nigeria: a cross-sectional study. *SAGE Open Med* 2019;7:205031219869109.

Galvan FH, Davis EM, Banks D. HIV stigma and social support among African Americans 2008;22:423–36.

Stephenson R. Community factors shaping HIV-related stigma among young people in three African countries. *AIDS Care* 2009;21:403–10.

Cianelli R, Villegas N, De Oliveira G, et al. Predictors of HIV enacted stigma among Chilean women. *J Clin Nurs* 2015;24:2392–401.

Li Z, Morano JP, Khoshnood K, et al. HIV-related stigma among people living with HIV/AIDS in rural Central China. *BMC Health Serv Res* 2018;18:453.

Chan BT, Tsai AC, Siedner MJ. HIV treatment scale-up and HIV-related stigma in sub-Saharan Africa: a longitudinal cross-Country analysis. *Am J Public Health* 2015;105:1581–7.

Wolfe WR, Weiser SD, Leiter K, et al. The impact of universal access to antiretroviral therapy on HIV stigma in Botswana. *Am J Public Health* 2008;98:1865–71.

Jürgensen M, Sandoz IF, Micheló C, et al. Effects of home-based voluntary counselling and testing on HIV-related stigma: findings from a cluster-randomized trial in Zambia. *Soc Sci Med* 2013;81:18–25.

Kemp CG, Lipira L, Huh D, et al. HIV stigma and viral load among African-American women receiving treatment for HIV. 2019;33:1511–9.